Claims for Patent: 9,283,357

Summary for Patent: 9,283,357

Title:	Methods, compositions and apparatus for delivering heterologous molecules to cells
Abstract:	A method for transferring a macromolecular complex to muscle cells by exsanguinating a region of the subject\'s microvasculature and delivering the complex to this region under high hydrostatic pressure. A balloon catheter having a balloon that extends substantially the full length of the cannula that is inserted into the subject is provided for use in the systemic delivery of macromolecular complex.
Inventor(s):	Stedman; Hansell H. (Norristown, PA), Bridges; Charles R. (Charlotte, NC)
Assignee:	The Trustees of the University of Pennsylvania (Philadelphia, PA)
Application Number:	14/621,532
Patent Claims:	1. A method for transferring a macromolecular complex to muscle cells in a subject, said method comprising the steps of exsanguinating a region of the subject's microvasculature; delivering a macromolecular complex to the exsanguinated region of the subject's microvasculature under high hydrostatic pressure that transfers the complex to the muscle cells. 2. The method according to claim 1, wherein said molecular complex is perfused in a physiologically compatible solution. 3. The method according to claim 1, wherein said macromolecular complex is perfused at about 50 mm Hg to about 500 mm Hg. 4. The method according to claim 1, wherein said macromolecular complex is perfused at about 100 mm Hg to about 400 mm Hg. 5. The method according to claim 1, wherein said macromolecular complex is perfused at about 100 mm Hg. 6. The method according to claim 1, wherein said macromolecular complex comprises a viral vector carrying a target molecule, wherein said viral vector is a recombinant adenoviral (rAd) vector or a recombinant adeno-associated viral (rAAV) vector. 7. The method according to claim 6, wherein said rAAV vector comprises an AAV1 capsid. 8. The method according to claim 6, wherein said recombinant rAAV vector comprises an AAV2 capsid. 9. The method according to claim 6, wherein said rAAV vector comprises AAV2 inverted terminal repeat sequences. 10. The method according to claim 6, wherein said recombinant rAAV vector comprises a serotype 1 capsid and serotype 2 inverted terminal repeat sequences. 11. The method according to claim 6, wherein said target molecule is a transgene, a chemical moiety, or a DNA molecule which directs the transcription of an mRNA molecule or a RNA silencing molecule. 12. The method according to claim 11, wherein said target molecule is a transgene. 13. The method according to claim 12, wherein said transgene encodes a sarcoglycan protein, dystrophin, utrophin, a minidystrophin protein, a microdystrophin protein, calpain, Fukutin, Fukutin-related protein, telethonin, laminin, beta adrenergic receptor kinase 1 (bARK1), beta andrenoreceptor kinase c-terminase (.beta.ARKct), carnitine palmityl transferase (CPT) 1, CTP2, dysferlin, thymidine phosphorylase; SMN2 (SMNC), insulin-like growth factor, sarcoplasmic reticulum Ca.sup.2+ ATPase (SERCA), or phoshpholambin. 14. The method according to claim 12, wherein said transgene encodes Factor VIII or Factor IX. 15. The method according to claim 12, wherein said transgene encodes a myostatin inhibitor, insulin, glucagon, growth hormone (GH), parathyroid hormone (PTH), growth hormone releasing factor (GRF), follicle stimulating hormone (FSH), luteinizing hormone (LH), human chorionic gonadotropin (hCG), vascular endothelial growth factor (VEGF), platelet derived growth factor (PDGF), angiopoietins, angiostatin, granulocyte colony stimulating factor (GCSF), erythropoietin (EPO), connective tissue growth factor (CTGF), basic fibroblast growth factor (bFGF), acidic fibroblast growth factor (aFGF), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), insulin growth factors I and II (IGF-I and IGF-II), TGF.alpha., an activin, an inhibin, a bone morphogenic protein (BMP), a heregluin/neuregulin/ARIA/neu differentiation factor (NDF) growth factor, nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin NT-3, neurotrophin NT-4/5, ciliary neurotrophic factor (CNTF), glial cell line derived neurotrophic factor (GDNF), neurturin, agrin, a semaphorin a collapsin, netrin-1, netrin-2, hepatocyte growth factor (HGF), an ephrin, noggin, sonic hedgehog or tyrosine hydroxylase. 16. The method according to claim 1, wherein the macromolecular complex is permitted to dwell for about 30 seconds to about 30 minutes. 17. The method according to claim 16, wherein macromolecular complex solution is permitted to dwell for about 90 seconds. 18. The method according to claim 1, wherein said region of the subject's microvasculature is exsanguinated by isolation and compression. 19. The method according to claim 18, wherein compression is achieved by wrapping of said region with an elastic band under force. 20. The method according to claim 1, wherein the exsanguinated region is flushed following delivery of the macromolecular complex.

Details for Patent 9,283,357

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	01/15/1974		2023-09-26
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	12/27/1984		2023-09-26
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	02/15/1985		2023-09-26
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	02/16/1990		2023-09-26
Bel-mar Laboratories, Inc.	CHORIONIC GONADOTROPIN	chorionic gonadotropin	Injection	017054	03/26/1974		2023-09-26